Anzeige
Mehr »
Sonntag, 31.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMC3 | ISIN: NL0015000YE1 | Ticker-Symbol: 0N6A
München
29.08.25 | 08:14
0,111 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TME PHARMA NV Chart 1 Jahr
5-Tage-Chart
TME PHARMA NV 5-Tage-Chart
RealtimeGeldBriefZeit
0,0900,11429.08.

Aktuelle News zur TME PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoTME Pharma N.V.: TME Pharma to raise €500k through new bond issue and receives new notice of shareholding275TME Pharma is raising additional funds to accelerate the Company's fundamental activities and to increase its budget for its treasury investment strategy TME Pharma has secured binding...
► Artikel lesen
29.07.TME Pharma N.V.: TME Pharma Provides Update About Additional Strategy501Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased...
► Artikel lesen
08.07.TME Pharma N.V.: TME Pharma: Termination of the Liquidity Contract398Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer and eye diseases, announced...
► Artikel lesen
30.06.TME Pharma N.V.: TME Pharma Announces New Treasury Investment Policy464Part of treasury funds can now be allocated to cryptocurrency-linked investments If successful, the company may consider expanding cryptocurrency strategies beyond treasury management to...
► Artikel lesen
TME PHARMA Aktie jetzt für 0€ handeln
27.06.TME Pharma N.V.: TME Pharma Provides Results of Final Exercise of Warrants Z4561,948 Warrants Z were exercised resulting in the issuance of 2,435 new ordinary shares Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company...
► Artikel lesen
25.06.TME Pharma N.V.: TME Pharma Appoints Diede van den Ouden as New CEO at the 2025 Annual General Meeting of Shareholders535Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
18.06.TME Pharma N.V.: TME Pharma Announces Successful Next Step in Its NOX-E36 Ophthalmology Strategy With Signature of Option Framework Agreement With Singapore Eye Research Institute (SERI)374Option framework agreement with SERI establishes ownership- and revenue-sharing model for all NOX-E36 ophthalmic disease rights TME Pharma to lead commercial discussions for potential spin-out...
► Artikel lesen
27.05.TME Pharma N.V.: TME Pharma Provides Additional Details on the Debt and Warrant Agreements Announced on 21 May That Extend Its Financial Visibility by 12 Months520The Company is hereby clarifying and providing additional information on the financing announced on May 21, 2025 TME Pharma has secured private binding commitments from professional European...
► Artikel lesen
26.05.TME Pharma N.V.: TME Pharma Announces Convocation of the 2025 Annual General Meeting of Shareholders882Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME),a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
21.05.TME Pharma N.V.: TME Pharma Extends Its Financial Visibility by 12 Months685TME Pharma secures binding commitments for €1.7M proceeds from regular bonds repayable in cash during 12-month maturity period The transaction extends financial visibility into May 2026...
► Artikel lesen
05.05.TME Pharma N.V.: TME Pharma Announces That Nominated CEO Plans to Increase His Shareholding406Diede van den Ouden has disclosed plans for initial share purchases to become a more significant shareholder in TME Pharma prior to his nomination for appointment as CEO at the upcoming AGM in...
► Artikel lesen
05.05.Chef- und Strategiewechsel bei TME Pharma15
05.05.TME Pharma N.V.: TME Pharma Announces New Strategy1.329Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appointment as CEO at upcoming AGM in June 2025 Operational costs to be...
► Artikel lesen
25.04.TME Pharma N.V.: TME Pharma Publishes 2024 Financial Results and Provides Operating Update450Total €7.6 million raised through multiple transactions All convertible debt instruments removed from balance sheet during 2024 Commitment to lean cost structure while focusing on...
► Artikel lesen
10.04.TME Pharma N.V.: TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities451Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
28.03.TME Pharma N.V.: TME Pharma Provides Results of Fifth Exercise of Warrants Z834556 Warrants Z were exercised resulting in the issuance of 695 new ordinary shares Outstanding 2,810,092 Warrants Z remain exercisable until June 20, 2025, with potential to raise up to...
► Artikel lesen
13.03.TME Pharma N.V.: TME Pharma Announces Filing of Patents for Use of CCL2 Inhibitor NOX-E36 in Ophthalmology and Presentation at ARVO 2025 of Preclinical Data Showing Benefit in Glaucoma Filtration Surgery560TME Pharma and Singapore Eye Research Institute (SERI) file new patent applications covering NOX-E36 for treatment of glaucoma filtration surgery and other ophthalmic diseases Preclinical...
► Artikel lesen
17.02.TME Pharma N.V.: TME Pharma CEO Message538Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor...
► Artikel lesen
29.01.TME Pharma N.V.: TME Pharma Announces Collaboration with aimed analytics for AI-Driven Drug Discovery and Optimization721New Capabilities aim to strengthen corporate profile for strategic transactions and reinforce ongoing partnering discussions Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME)...
► Artikel lesen
20.01.TME Pharma N.V.: TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities504Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment...
► Artikel lesen
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1